Historical Context of Drug Issues in NPB
Drug issues in NPB must be understood from two perspectives: performance-enhancing drugs (PEDs) and social drugs. Regarding PEDs, large-scale steroid contamination like MLB's has not been confirmed in NPB, though individual violation cases exist. On the other hand, regarding social drugs (stimulants, marijuana, etc.), incidents of active players being arrested have sent shockwaves through the baseball world. In 2016, a Yomiuri player was arrested for stimulant use, and the inadequacy of NPB's overall drug countermeasures was severely questioned. This incident forced a shift from NPB's stance of treating drug problems as 'individual issues.' Building a systematic drug testing framework became urgent, and NPB embarked on fundamental institutional reform.
Lessons from MLB's Steroid Era
From the late 1990s through the 2000s, MLB experienced the 'steroid era,' when performance-enhancing drugs including steroids were rampant. Behind the spectacular records of Mark McGwire and Sammy Sosa's home run race and Barry Bonds' record-breaking lay the shadow of doping. The 2003 BALCO scandal and the 2007 Mitchell Report exposed the severity of MLB's drug contamination. From this experience, MLB introduced a strict drug testing program and progressively strengthened penalties for violators. NPB aimed to build preventive drug countermeasures referencing MLB's lessons. However, compared to MLB, NPB's testing system remains relatively lenient, with differences in the frequency of random testing and the range of tested substances.
Building NPB's Anti-Doping Framework
NPB established its Anti-Doping Regulations in 2007 and began building a systematic drug testing framework. These regulations were designed as a unique framework adapted to professional baseball's characteristics while referencing World Anti-Doping Agency (WADA) standards. Testing is conducted through two tracks: random testing during the official season and regular testing during the off-season. Tested substances include anabolic steroids, growth hormones, stimulants, and diuretics. Penalties for confirmed violations are set progressively: a 20-game suspension for the first offense, a one-year suspension for the second, and permanent ban for the third. However, since NPB itself conducts the testing, ensuring independence has been identified as a challenge.
Books about MLB's steroid era are also helpful
Future Challenges and Outlook for Drug Regulation
While NPB's drug regulations have been steadily developed, many challenges remain for the future. First is ensuring testing independence. Under the current system, NPB handles both testing implementation and penalty decisions, and a transition to independent testing by a third-party organization is needed. Second is responding to new drugs. Next-generation substances that are difficult to detect with conventional testing, such as gene doping and selective androgen receptor modulators (SARMs), have emerged, requiring continuous updates to testing technology. Third is enhancing player education. Strengthening awareness activities regarding the risk of inadvertently ingesting prohibited substances (such as supplement contamination) is needed. For NPB to maintain trust as a clean sport, it must pursue both strengthened testing systems and player education in tandem.
Classification and Mechanisms of Major Performance-Enhancing Drugs
Performance-enhancing drugs regulated in anti-doping contexts fall into four main categories. First, anabolic steroids act as testosterone analogs that promote muscle hypertrophy and accelerate recovery. Second, human growth hormone (HGH) facilitates tissue repair and fat metabolism, often used to speed return from injury. Third, erythropoietin (EPO) stimulates red blood cell production, boosting aerobic capacity. Fourth, stimulants such as amphetamines temporarily heighten focus and alertness. Each substance differs in administration route, detection window, and side-effect profile, requiring testing programs to employ substance-specific detection methods.
Supplement Contamination and the Risk of Unintentional Positive Tests
A notable proportion of doping violations among professional athletes stem not from deliberate intake of banned substances but from prohibited compounds inadvertently present in supplements and nutritional products. WADA has reported that some supplement products contained banned substances not listed on labels, with cross-contamination during manufacturing cited as the primary cause. NPB's educational outreach recommends athletes use WADA-certified products and consult team nutritionists before taking supplements. However, the commercial supplement market is vast, making it practically impossible for individual athletes to verify the safety of every product they consume.
Therapeutic Use Exemptions and Athletes' Rights
When athletes need to use prohibited substances for legitimate medical purposes, the Therapeutic Use Exemption (TUE) system allows them to avoid violations. Based on WADA's international standards, TUE applications are reviewed by an independent medical committee and approved only when no alternative treatment exists and the substance does not enhance performance beyond restoring health. NPB operates a TUE process, though neither application numbers nor approval rates are publicly disclosed. For athletes, TUEs represent a vital mechanism balancing the right to medical treatment with fair enforcement of anti-doping rules, while greater transparency in the process is considered essential for maintaining public trust.